Skip to Content

Vistagen Therapeutics Inc VTGN

Morningstar Rating
$3.84 −0.07 (1.79%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

VTGN is trading at a 815% premium.
Price
$3.82
Fair Value
$4.19
Uncertainty
Extreme
1-Star Price
$14.68
5-Star Price
$9.47
Economic Moat
Rzf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VTGN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.91
Day Range
$3.733.96
52-Week Range
$1.6324.71
Bid/Ask
$3.70 / $3.99
Market Cap
$103.78 Mil
Volume/Avg
90,088 / 140,363

Key Statistics

Price/Earnings (Normalized)
Price/Sales
69.85
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
37

Valuation

Metric
VTGN
Price/Earnings (Normalized)
Price/Book Value
0.91
Price/Sales
69.85
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
VTGN
Quick Ratio
23.26
Current Ratio
23.55
Interest Coverage
Quick Ratio
VTGN

Profitability

Metric
VTGN
Return on Assets (Normalized)
−41.49%
Return on Equity (Normalized)
−47.29%
Return on Invested Capital (Normalized)
−49.66%
Return on Assets
VTGN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
RvsbshpqLfbb$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
KvfhlrmdwTbpsn$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
WlzkqdmPcqdzg$121.2 Bil
Moderna Inc
MRNA
YmmzcmdtKdnw$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
BlppnysfGmygclw$33.0 Bil
argenx SE ADR
ARGX
PrjvgngmDkzp$27.9 Bil
BioNTech SE ADR
BNTX
QbbltsjFxkdk$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
ZhwnhckgLfcbxr$16.1 Bil
United Therapeutics Corp
UTHR
XyggddwBlr$14.3 Bil
Incyte Corp
INCY
ZqnzmlvdxDgbmd$12.5 Bil

Sponsor Center